Last reviewed · How we verify
Netromycin (NETILMICIN)
At a glance
| Generic name | NETILMICIN |
|---|---|
| Drug class | Aminoglycoside Antibacterial |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 1983 |
Approved indications
Common side effects
Drug interactions
- pancuronium
- pipecuronium
- piperacillin
- rocuronium
- suxamethonium
- ticarcillin
- tubocurarine
- vancomycin
- vecuronium
Key clinical trials
- Oral Switch During Treatment of Left-sided Endocarditis Due to Multi-susceptible Streptococcus (PHASE3)
- Patients Response to Early Switch To Oral:Osteomyelitis Study (EARLY_PHASE1)
- Clinical Study to Evaluate the Efficacy and Tolerability of an Anti-inflammatory/Antibiotic Treatment Following Ocular Cataract Extraction (PHASE3)
- Early-onset Ventilator-associated Pneumonia in Adults: Comparison of 8 Versus 15 Days of Antibiotic Treatment (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Netromycin CI brief — competitive landscape report
- Netromycin updates RSS · CI watch RSS